SynthesisJNCI cancer spectrum2025
Risks of colorectal and extracolonic cancers following colorectal cancer: a systematic review and meta-analysis.
Synthesis in JNCI cancer spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Risk of developing subsequent primary breast cancer among non-breast cancer survivors: a retrospective cohort study.Breast cancer (Tokyo, Japan) · 2026Article
- Clinical utility of diagnosing Lynch syndrome in gynecologic oncology: a joint statement from four Japanese academic societies.International journal of clinical oncology · 2026Review
- Subsequent primary cancer risks for non-hereditary colorectal cancer survivors.EClinicalMedicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundColorectal cancer survivors face increased risks of developing new primary cancers in colorectum and other anatomical sites. This systematic review aimed to estimate primary colorectal and extracolonic cancers risks following colorectal cancer.
methodsPeer-reviewed articles published before January 2025 were screened across 4 databases to identify studies using population cancer registry reporting standardized incidence ratios (SIRs) of primary cancers following colorectal cancer, compared with the general population. A meta-analysis was conducted to summarize the SIRs, and age-specific cumulative risks of primary cancers following colorectal cancer were estimated using the summarized SIRs and age-, sex-, calendar-, region-, and cancer-specific incidence data.
resultsOf 8254 articles identified, 57 were included in meta-analysis. The pooled SIRs (95% confidence interval) for any primary cancer, extracolonic cancer and colorectal cancer were 1.13 (1.06 to 1.20), 1.10 (1.03 to 1.17), and 1.55 (1.33 to 1.77), respectively. Increased risks were also observed for primary cancers of small intestine, ovary, uterus, testes, kidney, female breast, thyroid, and prostate overall, as well as for lung and urinary bladder cancer in recent studies. The cumulative risks of any primary cancer, extracolonic cancer, and colorectal cancer to age 75 years were 38.5%, 31.6%, and 8.24% in Australasia; 33.8%, 30.9%, and 4.77% in North America; 27.4%, 25.6%, and 8.01% in East Asia; and 33.4%, 28.8%, and 4.68% in Europe.
conclusionColorectal cancer survivors have an increased risk of subsequent primary cancers, both extracolonic and colorectal, when compared with the general population. These findings underscore the necessity for tailored surveillance and prevention strategies to effectively identify and manage subsequent primary cancers in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.